Table 2.
Immediate and delayed risk reducing contralateral mastectomy (RRCM), differences between patients who had a predictive test versus diagnostic test
| RRCM | BREAST cancer diagnosis 1995–2000 | BREAST cancer diagnosis 2001–2009 | Total 1995–2009 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| N (%) | DNA test before diagnosis | DNA test after diagnosis | Sub-total | p | DNA test before diagnosis | DNA test after diagnosis | Sub-total | p | |
| Immediate RRCM | 9/20 (45.0 %) | 10/122 (8.2 %) | 19/142 (13.4 %) | <0.0001 | 12/41 (29.3 %) | 3/48 (6.2 %) | 15/89 (16.9 %) | 0.004 | 34/231 (14.7 %) |
| Delayed RRCMa | 7/11 (63.6 %) | 44/95 (46.3 %) | 51/106 (48.1 %) | 0.28 | 9/21 (42.9 %) | 13/24 (54.2 %) | 22/45 (48.9 %) | 0.45 | 73/151 (48.3 %) |
Only for patients with a primary unilateral breast cancer
Differences in uptake of RRCM between predictively and diagnostically tested women within and between 1995–2000 and 2001–2009 were analysed using Chi square tests
RRCM risk reducing contralateral mastectomy
aFor delayed RRCM, patients from LUMC were excluded